{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:57:09Z","timestamp":1789268229921,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euo.2023.11.024","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T20:17:33Z","timestamp":1703362653000},"page":"906-913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study"],"prefix":"10.1016","volume":"7","author":[{"given":"Ronald","family":"Tutrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Bailen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Saltzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.11.024_b0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2490-14-55","article-title":"Changing paradigms in management of metastatic castration resistant prostate cancer (mCRPC)","volume":"14","author":"Gupta","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2023.11.024_b0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.euo.2023.11.024_b0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/pcan.2012.25","article-title":"New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists","volume":"16","author":"Shore","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2023.11.024_b0020","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2023.11.024_b0025","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.urology.2004.07.033","article-title":"Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial","volume":"64","author":"Zinner","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euo.2023.11.024_b0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2023.11.024_b0035","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","article-title":"Gonadotropin-releasing hormone: an update review of the antagonists versus agonists","volume":"19","author":"Van Poppel","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2023.11.024_b0040","first-page":"626","article-title":"The role of LHRH antagonists in the treatment of prostate cancer","volume":"23","author":"Crawford","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.euo.2023.11.024_b0045","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1517\/14656566.5.10.2171","article-title":"Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer","volume":"5","author":"Mongiat-Artus","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.euo.2023.11.024_b0050","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.coph.2003.06.009","article-title":"Gonadotropin-releasing hormone antagonists","volume":"3","author":"Herbst","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.euo.2023.11.024_b0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756287211414457","article-title":"An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer","volume":"3","author":"Boccon-Gibod","year":"2011","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euo.2023.11.024_b0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1464-410X.2011.10728.x","article-title":"Androgen deprivation therapy before radical prostatectomy is associated with poorer postoperative erectile function outcomes","volume":"110","author":"Mazzola","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2023.11.024_b0065","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.11.024_b0070","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","article-title":"Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis","volume":"93","author":"Shahani","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euo.2023.11.024_b0075","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.11.024_b0080","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1743-6109.2010.02169.x","article-title":"Intermittent androgen suppression in prostate cancer: testosterone levels and its implication","volume":"8","author":"Mearini","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.euo.2023.11.024_b0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ejca.2006.01.029","article-title":"Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer","volume":"42","author":"Spry","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.11.024_b0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/pros.20341","article-title":"Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer","volume":"66","author":"Kaku","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2023.11.024_b0095","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jsxm.2019.03.273","article-title":"Testosterone recovery profiles after cessation of androgen deprivation therapy for prostate cancer","volume":"16","author":"Nascimento","year":"2019","journal-title":"J Sex Med"},{"key":"10.1016\/j.euo.2023.11.024_b0100","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/00365590600641533","article-title":"Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer","volume":"40","author":"Kobayashi","year":"2006","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.euo.2023.11.024_b0105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/21681805.2016.1227876","article-title":"Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer","volume":"50","author":"Planas","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2023.11.024_b0110","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.11.024_b0115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.024_b0120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/jco.2016.34.2_suppl.200","article-title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts)","volume":"34","author":"Saad","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.11.024_b0125","unstructured":"ORGOVYX (relugolix). Highlights of prescribing information. Myovant Sciences, Inc.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214621s000lbl.pdf. Accessed July 10, 2023."},{"key":"10.1016\/j.euo.2023.11.024_b0130","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. 2010."},{"key":"10.1016\/j.euo.2023.11.024_b0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.11.024_b0140","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:16:17Z","timestamp":1721110577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2588931123002900"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.024","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}